Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess metabolic plasma markers of insulin
resistance in patients with early-stage HER2-negative breast cancers receiving dapagliflozin
concomitant with neoadjuvant therapy.